Focusing on ‘Scheduled Drug – Processes and Complications in Global Logistics’, PCI’s Rich Nelson, Senior Manager, Global Logistics for Clinical Services, will present on Tuesday, May 14 at 9am PDT. Rich will share PCI’s significant experience, providing an overview of the differences and potential difficulties involved with the global movement of scheduled drugs. He will also discuss the impact of those processes on timelines and logistics plans for clinical trials.
In his role with PCI, Rich works with clients to provide seamless global distribution for their investigational drug products, ensuring cost-effective and time-efficient delivery throughout the clinical trials process.
“The process of handling scheduled drugs is highly complex, due to the inherent risks involved with the product, and the need for absolute compliance in its development, manufacturing and distribution. PCI has a long-standing track record of supporting clients across the world in this challenging area, and I am delighted to have the opportunity to share some of our insight and experience at the CTS West Coast event,” said Rich.
PCI recently announced expansion of its industry leading global controlled substance infrastructure, coinciding with new legislation from the US government in addressing concerns about the nations’ opioid crisis. PCI offers expertise in packaging and logistics for controlled substances, approved for Schedule I – V DEA designations. PCI’s domestic operations are located in Philadelphia, PA, Rockford, IL, and San Diego, CA, complemented by operations in the UK, Ireland and Australia.
PCI is a trusted partner for the global healthcare industry and has been providing development solutions that increase client’s products' speed to market and opportunities for commercial success. PCI has proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Many clients view PCI as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives.
For further information about PCI’s expertise in scheduled drug processes, please visit here.
